| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRBV19 |
| Uniprot No | A0A075B6N1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-114 aa |
| 活性数据 | GITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSI |
| 分子量 | 16.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人TRBV19蛋白的3-4篇参考文献的简要概述(注：以下为模拟示例，实际文献需通过数据库检索确认)：
---
1. **文献名称**: *Structural characterization of the human TRBV19 T-cell receptor beta chain*
**作者**: Müller, R. et al. (2022)
**摘要**: 该研究通过重组表达技术在大肠杆菌中生产了TRBV19蛋白，并利用X射线晶体学解析其三维结构。结果揭示了TRBV19的抗原结合域构象及其与特定MHC-多肽复合物相互作用的潜在机制，为T细胞受体工程提供了结构基础。
---
2. **文献名称**: *Recombinant TRBV19 expression and its role in autoimmune profiling*
**作者**: Zhao, L. et al. (2018)
**摘要**: 本研究构建了重组TRBV19蛋白的真核表达系统，并验证其在类风湿关节炎患者外周血中的异常表达。通过ELISA和流式细胞术，发现TRBV19与自身抗原的亲和力升高，提示其可能作为自身免疫疾病的生物标志物。
---
3. **文献名称**: *High-yield purification and functional analysis of recombinant TRBV19 in T-cell activation*
**作者**: Smith, J. et al. (2020)
**摘要**: 文章优化了TRBV19蛋白的原核表达条件，利用亲和层析技术实现高纯度制备。功能实验表明，重组TRBV19能特异性识别病毒抗原并激活T细胞，为基于TCR的免疫疗法开发提供参考。
---
4. **文献名称**: *TRBV19-specific signatures in tumor-infiltrating lymphocytes: Insights from recombinant protein screening*
**作者**: Gupta, S. et al. (2019)
**摘要**: 通过重组TRBV19蛋白筛选肿瘤微环境中的T细胞克隆，发现其与特定肿瘤抗原的交叉反应性，暗示TRBV19可能参与抗肿瘤免疫应答，为个性化癌症疫苗设计提供新思路。
---
如需具体文献，建议通过**PubMed**或**Web of Science**检索关键词“recombinant TRBV19 protein”或“TRBV19 T-cell receptor expression”获取全文。
The T-cell receptor beta variable 19 (TRBV19) is a segment of the T-cell receptor (TCR) beta chain, a critical component of the adaptive immune system. TCRs recognize antigenic peptides presented by major histocompatibility complex (MHC) molecules, initiating immune responses. The TRBV19 gene encodes the variable region of the beta chain, contributing to TCR diversity through genetic recombination with diversity (D) and joining (J) segments. This variability enables T cells to identify a vast array of antigens. Recombinant TRBV19 protein is typically produced using expression systems like *E. coli* or mammalian cells, allowing researchers to study its structural and functional properties. It is pivotal in investigating TCR-pMHC interactions, T-cell development, and antigen specificity. Additionally, recombinant TRBV19 aids in therapeutic research, such as designing TCR-based therapies for cancers or autoimmune diseases. Its study also sheds light on clonal T-cell expansions in infections or malignancies. Structural analyses of TRBV19 help map epitope-binding regions and engineer high-affinity TCRs for immunotherapy. Understanding TRBV19’s role enhances insights into immune dysregulation and supports the development of targeted immunotherapies.
×
